Search results
Results from the WOW.Com Content Network
One study published in December 2022 found that semaglutide lowered the risk of dementia in patients with type 2 diabetes. Another study found that fellow GLP-1 medication liraglutide may protect ...
Researchers are investigating whether diabetes and eye disease drugs could also be used to treat or even prevent dementia. Scientists at the University of Manchester are studying methazolamide, a ...
However, while dementia risk is higher in people with type 2 diabetes, it is not inevitable. Managing diabetes with medication, and making healthy lifestyle changes could significantly reduce a ...
Type 3 diabetes is a proposed pathological linkage between Alzheimer's disease and certain features of type 1 and type 2 diabetes. [1] Specifically, the term refers to a set of common biochemical and metabolic features seen in the brain in Alzheimer's disease, and in other tissues in diabetes; [1] [2] it may thus be considered a "brain-specific type of diabetes."
Alzheimer's disease (AD) is a neurodegenerative disease that usually starts slowly and progressively worsens, [ 2 ] and is the cause of 60–70% of cases of dementia. [ 2 ][ 15 ] The most common early symptom is difficulty in remembering recent events. [ 1 ] As the disease advances, symptoms can include problems with language, disorientation ...
The prevention of dementia involves reducing the number of risk factors for the development of dementia, and is a global health priority needing a global response. [1] [2] Initiatives include the establishment of the International Research Network on Dementia Prevention (IRNDP) [3] which aims to link researchers in this field globally, and the establishment of the Global Dementia Observatory ...
Parkinson’s disease and Alzheimer’s disease risk are lowered in people who take a type of type 2 diabetes drug, a study from South Korea has shown. Researchers from Yonsei University College ...
SGLT2 inhibitors lowered dementia, Parkinson’s risk by 22%. For this study, the researchers accessed data from 358,862 participants with type 2 diabetes and followed them for an average of 9.6 ...